Work

Implementing flexible and adapted follow-up strategies in a patient-centric, phase II trial of first-line lorlatinib for advanced ALK-positive non–small cell lung cancer (CTONG2203).

Year: 2026

Type: article

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2026.44.16_suppl.e13545

Authors: Jia-Xin Lin, Qing Zhou, Hong-Hong Yan, Qian Chu, Guowu Wu, Anwen Liu, Jiuwei Cui, Ying Liu, Haipeng Xu, Yingying Du, Yi Yang, HaiYan Tu, Yi-Long Wu, Si-Yang Maggie Liu

Institutions: Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Tongji Hospital, Huazhong University of Science and Technology, Sun Yat-sen University, Meizhou City People's Hospital, Second Affiliated Hospital of Nanchang University, First Hospital of Jilin University, Jilin Province Tumor Hospital, Fujian Provincial Cancer Hospital, First Affiliated Hospital of Anhui Medical University, Third People's Hospital of Chengdu, Southwest Jiaotong University

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7162697201

FWCI:

Cites:

Cited by:

Related to: